gabapentin has been researched along with Benign Neoplasms in 43 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The inclusion criteria are adult patients with cancer suffering from neuropathic cancer pain refractory to opioids and gabapentinoids, patients with a Numerical Rating Scale (NRS) pain score of 4 or higher and patients with a total Hospital Anxiety and Depression Scale score of less than 20." | 9.24 | Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study. ( Ariyoshi, K; Ishiki, H; Iwase, S; Kawaguchi, T; Kizawa, Y; Koyama, A; Matsuda, Y; Matsuoka, H; Miyaji, T; Morita, T; Yamaguchi, T, 2017) |
| "The clinical usefulness of gabapentin in combination with opioids for Japanese patients with neuropathic cancer pain was assessed in an open-label, single-center, prospective study." | 9.14 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010) |
| "Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally." | 9.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "We conclude that gabapentin is an effective treatment for cancer-related neuropathic pain." | 9.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| " At our institution, new-onset seizures in children on chemotherapy are treated with gabapentin, a nonhepatic enzyme inducer." | 9.11 | Gabapentin to control seizures in children undergoing cancer treatment. ( Hunt, DL; Khan, RB; Thompson, SJ, 2004) |
| "The aim of our study was to explore a potential analgesic effect of gabapentin in patients with neuropathic pain caused by anticancer treatment." | 9.10 | Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study. ( Bosnjak, S; Jelic, S; Luki, V; Susnjar, S, 2002) |
| "Gabapentin (GBP), originally an antiepileptic drug, is more commonly used in the treatment of neuropathic pain." | 8.90 | Beyond neuropathic pain: gabapentin use in cancer pain and perioperative pain. ( Butler, PM; Kurowski, D; Perloff, MD; Yan, PZ, 2014) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 8.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Morphine infusion through Intrathecal Drug Delivery System (IDDS) is widely used to relieve refractory cancer pain." | 8.02 | Gabapentin enhances the antinociceptive effect of intrathecal morphine in refractory cancer pain patients. ( Dai, J; Lin, S; Shao, H; Teng, L; Zhang, W; Zhao, L; Zou, H, 2021) |
| "Gabapentin/placebo was started the day of chemotherapy and continued through day 5 for the first chemotherapy cycle, whereas dex was titrated down on days 2-4." | 6.79 | Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). ( Barton, DL; Blair, SC; Diekmann, B; Fuloria, J; Jaslowski, AJ; Kottschade, LA; Loprinzi, CL; Lyss, AP; Mazurczak, MA; Sloan, JA; Terstriep, S; Thanarajasingam, G, 2014) |
| "Gabapentin is a potential option to manage PLP after amputation in pediatric oncology." | 5.62 | Gabapentin for phantom limb pain after amputation in pediatric oncology: a systematic review protocol. ( Bai, JH; Jiang, S; Xia, R; Yan, LH; Zhou, MM, 2021) |
| "We prospectively followed 20 cancer patients with advanced disease suffering from neuropathic pain." | 5.32 | [Gabapentin (Neurontin) and cancer pain: a pilot study]. ( Body, JJ; Lossignol, DA; Plehiers, B, 2004) |
| " The inclusion criteria are adult patients with cancer suffering from neuropathic cancer pain refractory to opioids and gabapentinoids, patients with a Numerical Rating Scale (NRS) pain score of 4 or higher and patients with a total Hospital Anxiety and Depression Scale score of less than 20." | 5.24 | Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study. ( Ariyoshi, K; Ishiki, H; Iwase, S; Kawaguchi, T; Kizawa, Y; Koyama, A; Matsuda, Y; Matsuoka, H; Miyaji, T; Morita, T; Yamaguchi, T, 2017) |
| "Paclitaxel can cause an acute pain syndrome (P-APS), considered to be an acute form of neuropathy and chronic chemotherapy-induced peripheral neuropathy (CIPN)." | 5.22 | Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial. ( Atherton, PJ; Lafky, J; Loprinzi, CL; Pachman, DR; Ruddy, KJ; Seisler, D; Shinde, SS; Soori, G, 2016) |
| "Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally." | 5.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "The clinical usefulness of gabapentin in combination with opioids for Japanese patients with neuropathic cancer pain was assessed in an open-label, single-center, prospective study." | 5.14 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010) |
| "We conclude that gabapentin is an effective treatment for cancer-related neuropathic pain." | 5.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| " At our institution, new-onset seizures in children on chemotherapy are treated with gabapentin, a nonhepatic enzyme inducer." | 5.11 | Gabapentin to control seizures in children undergoing cancer treatment. ( Hunt, DL; Khan, RB; Thompson, SJ, 2004) |
| "The aim of our study was to explore a potential analgesic effect of gabapentin in patients with neuropathic pain caused by anticancer treatment." | 5.10 | Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study. ( Bosnjak, S; Jelic, S; Luki, V; Susnjar, S, 2002) |
| " Overall, there was a low quality of evidence that gabapentin, pregabalin, amitriptyline, and venlafaxine were effective in reducing pain intensity in patients with cancer pain." | 4.95 | Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review. ( de Graeff, A; Dijkstra, D; Jongen, JL; Mostovaya, I; van den Beuken-van Everdingen, MH; Vissers, KC, 2017) |
| "Gabapentin (GBP), originally an antiepileptic drug, is more commonly used in the treatment of neuropathic pain." | 4.90 | Beyond neuropathic pain: gabapentin use in cancer pain and perioperative pain. ( Butler, PM; Kurowski, D; Perloff, MD; Yan, PZ, 2014) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 4.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Morphine infusion through Intrathecal Drug Delivery System (IDDS) is widely used to relieve refractory cancer pain." | 4.02 | Gabapentin enhances the antinociceptive effect of intrathecal morphine in refractory cancer pain patients. ( Dai, J; Lin, S; Shao, H; Teng, L; Zhang, W; Zhao, L; Zou, H, 2021) |
| "Gabapentinoid use for long-term cancer pain control may be problematic, given unclear mechanisms of action and increased concerns for physical dependence." | 3.96 | Use of gabapentinoid medications among US adults with cancer, 2005-2015. ( Choi, SW; Davis, MA; Fauer, AJ; Friese, CR; Wallner, LP, 2020) |
| " Data pertaining to demographics, diagnosis, oral morphine dose equivalent of the opioid at the time of discharge, adjuvant analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and pain scores as reported by nurses and physicians were collected." | 3.81 | Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements? ( Davis, MP; Gordon, P; Gross, J; Sharma, P; Shinde, S, 2015) |
| "Little is known about current practice in using the anticonvulsant gabapentin in the management of cancer-related neuropathic pain." | 3.72 | The pattern of gabapentin use in a tertiary palliative care unit. ( al-Shahri, MZ; Oneschuk, D, 2003) |
| "Managing cancer-related pain in patients who are also pregnant compounds the challenge for adequate pain management, as studies have largely excluded this population." | 3.01 | Pharmacologic Management of Cancer-Related Pain in Pregnant Patients. ( McGinn, R; Smith, MA; Zerfas, I, 2023) |
| "Gabapentin/placebo was started the day of chemotherapy and continued through day 5 for the first chemotherapy cycle, whereas dex was titrated down on days 2-4." | 2.79 | Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). ( Barton, DL; Blair, SC; Diekmann, B; Fuloria, J; Jaslowski, AJ; Kottschade, LA; Loprinzi, CL; Lyss, AP; Mazurczak, MA; Sloan, JA; Terstriep, S; Thanarajasingam, G, 2014) |
| "Neuropathic pain is difficult to diagnose and difficult to treat with certainty." | 2.77 | A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. ( Bhatnagar, S; Goyal, GN; Mishra, S; Rana, SP; Upadhya, SP, 2012) |
| "Neuropathic cancer pain represents a major challenge." | 2.73 | Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial. ( Aydinli, I; Keskinbora, K; Pekel, AF, 2007) |
| "Gabapentin was administered as an "add on" therapy to 22 patients with neuropathic cancer pain only partially responsive to opioid therapy." | 2.69 | Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. ( Caraceni, A; De Conno, F; Martini, C; Zecca, E, 1999) |
| "A third of female patients with cancer report dissatisfaction with the quality and length of physician-patient discussions about reproductive health, including menopause." | 2.58 | Managing menopausal symptoms after cancer: an evidence-based approach for primary care. ( Hickey, M; Marino, JL; McNamara, HC, 2018) |
| "Neuropathic pain is caused by a lesion or disease of the somatosensory system, including peripheral fibres (Aβ, Aδ and C fibres) and central neurons, and affects 7-10% of the general population." | 2.55 | Neuropathic pain. ( Attal, N; Baron, R; Bennett, DL; Bouhassira, D; Colloca, L; Dickenson, AH; Dworkin, RH; Eccleston, C; Finnerup, NB; Freeman, R; Kalso, E; Ludman, T; Raja, SN; Truini, A; Yarnitsky, D, 2017) |
| "Opioid-induced hyperalgesia has recently been described as representing a challenge for physicians in the clinical setting." | 2.50 | Managing difficult pain conditions in the cancer patient. ( Mercadante, S, 2014) |
| "Neuropathic pain is usually considered an "hard pain" both for the intrinsic difficulties in a correct diagnosis, and for the modest efficacy of the most part of conventional treatments." | 2.47 | [Neuropathic pain in oncology. Novel evidence for clinical practice]. ( Carloni, F; Castellani, C; Drudi, F; Possenti, C; Santelmo, C; Tassinari, D, 2011) |
| "Gabapentin is a potential option to manage PLP after amputation in pediatric oncology." | 1.62 | Gabapentin for phantom limb pain after amputation in pediatric oncology: a systematic review protocol. ( Bai, JH; Jiang, S; Xia, R; Yan, LH; Zhou, MM, 2021) |
| "Gabapentin-cancer associations." | 1.51 | Gabapentin and Cancer Risk: Updated Findings from Kaiser Permanente Northern California. ( Achacoso, N; Friedman, GD; Habel, LA, 2019) |
| "These cancers were not statistically significantly associated with gabapentin in the GPRD case-control studies (2-year lag)." | 1.38 | Risk of cancer in patients exposed to gabapentin in two electronic medical record systems. ( Boudiaf, N; Friedman, GD; Habel, LA; Irizarry, MC; Logie, J; Udaltsova, N; Webb, DJ, 2012) |
| "Three patients with cancer experienced severe side-effects after starting anti-neuropathic pain therapy." | 1.37 | [Pitfalls in the treatment of neuropathic pain in patients with cancer]. ( Engels, Y; Hekster, YA; Schalkwijk, A; Verhagen, CA; Vissers, KC, 2011) |
| "4%) with gabapentin at a dosage of 900 mg/d and in 9 patients (20." | 1.36 | Gabapentin in the treatment of hiccups in patients with advanced cancer: a 5-year experience. ( Aielli, F; Aloisi, P; Ficorella, C; Galletti, B; Porzio, G; Verna, L, 2010) |
| "Gabapentin seems to be a safe and effective treatment for idiopathic sweating in advanced cancer patients." | 1.33 | Gabapentin in the treatment of severe sweating experienced by advanced cancer patients. ( Aielli, F; Aloisi, P; Cannita, K; Ficorella, C; Marchetti, P; Porto, C; Porzio, G; Ricevuto, E; Verna, L, 2006) |
| "Four were cancer patients and one suffered from neuropathic pain in the neck (C3)." | 1.33 | Experience with gabapentin for neuropathic pain in adolescents: report of five cases. ( Butkovic, D; Mihovilovic-Novak, B; Toljan, S, 2006) |
| "Gabapentin was the most widely used AED (92% of all AED patients); amitriptyline was the most widely used TCA (79% of all TCA patients)." | 1.33 | Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain. ( Berger, A; Dukes, E; Mercadante, S; Oster, G, 2006) |
| "We prospectively followed 20 cancer patients with advanced disease suffering from neuropathic pain." | 1.32 | [Gabapentin (Neurontin) and cancer pain: a pilot study]. ( Body, JJ; Lossignol, DA; Plehiers, B, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.65) | 18.2507 |
| 2000's | 15 (34.88) | 29.6817 |
| 2010's | 22 (51.16) | 24.3611 |
| 2020's | 4 (9.30) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Zerfas, I | 1 |
| McGinn, R | 1 |
| Smith, MA | 1 |
| Fauer, AJ | 1 |
| Davis, MA | 1 |
| Choi, SW | 1 |
| Wallner, LP | 1 |
| Friese, CR | 1 |
| Jiang, S | 1 |
| Zhou, MM | 1 |
| Xia, R | 1 |
| Bai, JH | 1 |
| Yan, LH | 1 |
| Teng, L | 1 |
| Dai, J | 1 |
| Shao, H | 1 |
| Zhao, L | 1 |
| Lin, S | 1 |
| Zhang, W | 1 |
| Zou, H | 1 |
| Matsuoka, H | 1 |
| Ishiki, H | 1 |
| Iwase, S | 1 |
| Koyama, A | 1 |
| Kawaguchi, T | 1 |
| Kizawa, Y | 1 |
| Morita, T | 1 |
| Matsuda, Y | 1 |
| Miyaji, T | 1 |
| Ariyoshi, K | 1 |
| Yamaguchi, T | 1 |
| Marino, JL | 1 |
| McNamara, HC | 1 |
| Hickey, M | 1 |
| Friedman, GD | 2 |
| Achacoso, N | 1 |
| Habel, LA | 2 |
| Yan, PZ | 1 |
| Butler, PM | 1 |
| Kurowski, D | 1 |
| Perloff, MD | 1 |
| Mercadante, S | 3 |
| Hershman, DL | 1 |
| Lacchetti, C | 1 |
| Dworkin, RH | 2 |
| Lavoie Smith, EM | 1 |
| Bleeker, J | 1 |
| Cavaletti, G | 1 |
| Chauhan, C | 1 |
| Gavin, P | 1 |
| Lavino, A | 1 |
| Lustberg, MB | 1 |
| Paice, J | 1 |
| Schneider, B | 1 |
| Smith, ML | 1 |
| Smith, T | 1 |
| Terstriep, S | 2 |
| Wagner-Johnston, N | 1 |
| Bak, K | 1 |
| Loprinzi, CL | 3 |
| Barton, DL | 1 |
| Thanarajasingam, G | 1 |
| Sloan, JA | 1 |
| Diekmann, B | 1 |
| Fuloria, J | 1 |
| Kottschade, LA | 1 |
| Lyss, AP | 1 |
| Jaslowski, AJ | 1 |
| Mazurczak, MA | 1 |
| Blair, SC | 1 |
| Shinde, S | 1 |
| Gordon, P | 1 |
| Sharma, P | 1 |
| Gross, J | 1 |
| Davis, MP | 1 |
| Shinde, SS | 1 |
| Seisler, D | 1 |
| Soori, G | 1 |
| Atherton, PJ | 1 |
| Pachman, DR | 1 |
| Lafky, J | 1 |
| Ruddy, KJ | 1 |
| Kottschade, L | 1 |
| Novotny, P | 1 |
| Lyss, A | 1 |
| Mazurczak, M | 1 |
| Loprinzi, C | 1 |
| Barton, D | 1 |
| van den Beuken-van Everdingen, MH | 1 |
| de Graeff, A | 1 |
| Jongen, JL | 1 |
| Dijkstra, D | 1 |
| Mostovaya, I | 1 |
| Vissers, KC | 2 |
| Colloca, L | 1 |
| Ludman, T | 1 |
| Bouhassira, D | 1 |
| Baron, R | 1 |
| Dickenson, AH | 1 |
| Yarnitsky, D | 1 |
| Freeman, R | 1 |
| Truini, A | 1 |
| Attal, N | 1 |
| Finnerup, NB | 1 |
| Eccleston, C | 1 |
| Kalso, E | 1 |
| Bennett, DL | 1 |
| Raja, SN | 1 |
| Taira, T | 1 |
| Takahashi, H | 1 |
| Shimoyama, N | 1 |
| Arai, YC | 1 |
| Matsubara, T | 1 |
| Shimo, K | 1 |
| Suetomi, K | 1 |
| Nishihara, M | 1 |
| Ushida, T | 1 |
| Kobayashi, K | 1 |
| Suzuki, C | 1 |
| Kinoshita, A | 1 |
| Kondo, M | 1 |
| Matsubara, S | 1 |
| Hayashi, R | 1 |
| Tohyama, Y | 1 |
| Nishida, K | 1 |
| Arakawa, M | 1 |
| Porzio, G | 2 |
| Aielli, F | 2 |
| Verna, L | 2 |
| Aloisi, P | 2 |
| Galletti, B | 1 |
| Ficorella, C | 2 |
| Bar Ad, V | 1 |
| Sirven, JI | 1 |
| Schalkwijk, A | 1 |
| Verhagen, CA | 1 |
| Engels, Y | 1 |
| Hekster, YA | 1 |
| Tassinari, D | 1 |
| Drudi, F | 1 |
| Carloni, F | 1 |
| Possenti, C | 1 |
| Santelmo, C | 1 |
| Castellani, C | 1 |
| Mishra, S | 1 |
| Bhatnagar, S | 1 |
| Goyal, GN | 1 |
| Rana, SP | 1 |
| Upadhya, SP | 1 |
| Irizarry, MC | 1 |
| Webb, DJ | 1 |
| Boudiaf, N | 1 |
| Logie, J | 1 |
| Udaltsova, N | 1 |
| Anand, S | 1 |
| Oneschuk, D | 1 |
| al-Shahri, MZ | 1 |
| Khan, RB | 1 |
| Hunt, DL | 1 |
| Thompson, SJ | 1 |
| Lossignol, DA | 1 |
| Plehiers, B | 1 |
| Body, JJ | 1 |
| Ross, JR | 1 |
| Goller, K | 1 |
| Hardy, J | 1 |
| Riley, J | 1 |
| Broadley, K | 1 |
| A'hern, R | 1 |
| Williams, J | 1 |
| Porto, C | 1 |
| Cannita, K | 1 |
| Ricevuto, E | 1 |
| Marchetti, P | 1 |
| Butkovic, D | 1 |
| Toljan, S | 1 |
| Mihovilovic-Novak, B | 1 |
| Berger, A | 1 |
| Dukes, E | 1 |
| Oster, G | 1 |
| Choudhuri, I | 1 |
| Sarvananthan, N | 1 |
| Gottlob, I | 1 |
| Keskinbora, K | 1 |
| Pekel, AF | 1 |
| Aydinli, I | 1 |
| McCaffery, M | 1 |
| Caraceni, A | 2 |
| Zecca, E | 2 |
| Martini, C | 2 |
| De Conno, F | 2 |
| Chandler, A | 1 |
| Williams, JE | 1 |
| Villari, P | 1 |
| Fulfaro, F | 1 |
| Bosnjak, S | 1 |
| Jelic, S | 1 |
| Susnjar, S | 1 |
| Luki, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&E Procedure: a Randomized Controlled Trial[NCT03080493] | Phase 4 | 121 participants (Actual) | Interventional | 2017-03-20 | Completed | ||
| Pain Phenotyping of Patients With Bone Cancer Pain[NCT03908853] | 70 participants (Anticipated) | Observational | 2019-02-05 | Recruiting | |||
| Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy[NCT04920097] | 240 participants (Anticipated) | Interventional | 2021-07-08 | Recruiting | |||
| Intravenous Lidocaine Infusion Versus Oral Duloxetine For The Prevention And Treatment Of Chemotherapy Induced Peripheral Neuropathy Among Breast Cancer Patients[NCT04732455] | 60 participants (Actual) | Interventional | 2021-01-15 | Completed | |||
| The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer[NCT04558034] | 14 participants (Actual) | Interventional | 2020-08-04 | Terminated (stopped due to Principal Investigator retired before study completed.) | |||
| Effect of Cryotherapy in Controlling Peripheral Neuropathy in Cancer Children[NCT04536207] | 60 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | |||
| Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer[NCT02549534] | 29 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)[NCT04780854] | Phase 2 | 68 participants (Anticipated) | Interventional | 2020-11-03 | Recruiting | ||
| Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ)[NCT04299893] | Phase 2/Phase 3 | 42 participants (Anticipated) | Interventional | 2020-11-30 | Recruiting | ||
| Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients: a Prospective, Randomized, Sham-controlled, Double-blinded and Multicenter Study[NCT05798884] | 150 participants (Anticipated) | Interventional | 2023-05-31 | Not yet recruiting | |||
| PUCE Study: Prevention of Unmitigated Chemotherapy-induced Emesis[NCT03996863] | 0 participants (Actual) | Interventional | 2019-08-01 | Withdrawn (stopped due to Drexel Oncology was shut down a few days before first patient in.) | |||
| Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management: A Randomized Controlled Trial of Efficacy and Safety[NCT05427058] | 36 participants (Anticipated) | Interventional | 2022-08-01 | Not yet recruiting | |||
| BotulInum Toxin Type A for Peripheral Neuropathic Pain in subjEcts With Carpal Tunnel Syndrome: a Multicenter, Randomized, Doubleblind, Placebo-controlled Study[NCT05411900] | Phase 2 | 164 participants (Anticipated) | Interventional | 2022-05-25 | Recruiting | ||
| Neuropathic Foot and Ankle in Rheumatoid Arthritis : Ultrasound and Nerve Conduction Study[NCT04550884] | 80 participants (Anticipated) | Observational | 2020-10-31 | Not yet recruiting | |||
| NanaBis™ an Oro-buccal Administered Equimolar d9-THC & CBD Formulation as Monotherapy for Management of Opioid Requiring Bone Pain Due to Metastatic Cancer: Phase 3 Multi Centre Blinded Randomized Withdrawal Active & Placebo Controlled Trial[NCT04808531] | Phase 3 | 360 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
| Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.[NCT06030297] | 301 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| Double Blind Trial Investigating the Role of Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients[NCT03847311] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-05-03 | Recruiting | ||
| Randomized Phase II Trial Evaluating Activity and Tolerability of Fixed Dose of Oxycodone and Increasing Dose of Pregabalin Versus Increasing Dose of Oxycodone and Fixed Dose of Pregabalin for the Treatment of Oncological Neuropathic Pain[NCT00637975] | Phase 2 | 80 participants (Anticipated) | Interventional | 2007-09-30 | Completed | ||
| Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187] | 8 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to PI left institution) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message. (NCT03080493)
Timeframe: 2 hours after insertion of last osmotic dilator
| Intervention | Numeric rating scale pain score change (Median) |
|---|---|
| Gabapentin | 3.5 |
| Placebo Oral Capsule | 4 |
Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message. (NCT03080493)
Timeframe: 4 hours after insertion of last osmotic dilator
| Intervention | Numeric rating scale pain score change (Mean) |
|---|---|
| Gabapentin | 3 |
| Placebo Oral Capsule | 3.5 |
Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained in person before subject leaves clinic appointment. (NCT03080493)
Timeframe: 5 minutes after insertion of last osmotic dilator
| Intervention | Numeric rating scale pain score change (Median) |
|---|---|
| Gabapentin | 1 |
| Placebo Oral Capsule | 2 |
Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message. (NCT03080493)
Timeframe: 8 hours after insertion of last osmotic dilator
| Intervention | Numeric rating scale pain score change (Median) |
|---|---|
| Gabapentin | 2 |
| Placebo Oral Capsule | 2.5 |
Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained in person upon presentation for D&E procedure. (NCT03080493)
Timeframe: Time of presentation for D&E (day after dilator insertion)
| Intervention | Numeric rating scale pain score change (Median) |
|---|---|
| Gabapentin | 0.5 |
| Placebo Oral Capsule | 1 |
Subject account of how many used acetaminophen/codeine (standard medications given for supplement NSAID as needed after dilator insertion) (NCT03080493)
Timeframe: Collected between each subject contact (2 hours, 4 hours, 8 hours after dilator insertion and at time of presentation for D&E procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin | 35 |
| Placebo Oral Capsule | 40 |
11 reviews available for gabapentin and Benign Neoplasms
| Article | Year |
|---|---|
Pharmacologic Management of Cancer-Related Pain in Pregnant Patients.
Topics: Analgesics; Analgesics, Opioid; Cancer Pain; Duloxetine Hydrochloride; Female; Gabapentin; Humans; N | 2023 |
Managing menopausal symptoms after cancer: an evidence-based approach for primary care.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Amenorrhea; Anti-Anxiety Agents; Breast Neoplasms; Canc | 2018 |
Beyond neuropathic pain: gabapentin use in cancer pain and perioperative pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neopla | 2014 |
Managing difficult pain conditions in the cancer patient.
Topics: Amines; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Breakthrough Pain; Cyclohexanec | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review.
Topics: Amines; Analgesics; Anticonvulsants; Antidepressive Agents; Chemotherapy, Adjuvant; Cyclohexanecarbo | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
[Chronic intrathecal drug administration for the control of intractable pain].
Topics: Amines; Analgesics, Opioid; Anesthetics, Local; Baclofen; Calcium Channel Blockers; Clonidine; Cyclo | 2008 |
Gabapentin for the treatment of cancer-related pain syndromes.
Topics: Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2010 |
[Neuropathic pain in oncology. Novel evidence for clinical practice].
Topics: Amines; Amitriptyline; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2011 |
Gabapentin for pruritus in palliative care.
Topics: Amines; Analgesics, Opioid; Burns; Cholestasis; Cyclohexanecarboxylic Acids; Dermatologic Agents; Ga | 2013 |
12 trials available for gabapentin and Benign Neoplasms
| Article | Year |
|---|---|
Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study.
Topics: Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Cancer Pain; Cyclohexanecarboxylic Acids; Doubl | 2017 |
Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance).
Topics: Adult; Aged; Amines; Antineoplastic Agents; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug A | 2014 |
Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial.
Topics: Acute Pain; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2016 |
Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).
Topics: Adult; Aged; Amines; Antiemetics; Antineoplastic Agents; Cisplatin; Cyclohexanecarboxylic Acids; Dru | 2016 |
A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain.
Topics: Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Female; Gabapentin | 2010 |
Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine.
Topics: Aged; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; | 2010 |
A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study.
Topics: Adult; Amines; Amitriptyline; Analgesics; Analysis of Variance; Cyclohexanecarboxylic Acids; Double- | 2012 |
Gabapentin to control seizures in children undergoing cancer treatment.
Topics: Acetates; Amines; Anticonvulsants; Antineoplastic Agents; Brain; Child; Cyclohexanecarboxylic Acids; | 2004 |
Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study.
Topics: Aged; Amines; Analgesics; Analysis of Variance; Cyclohexanecarboxylic Acids; Dose-Response Relations | 2005 |
Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial.
Topics: Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Therapy, Comb | 2007 |
Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Cyclohexane | 1999 |
Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study.
Topics: Acetates; Adolescent; Amines; Analgesics; Antineoplastic Agents; Cyclohexanecarboxylic Acids; Female | 2002 |
20 other studies available for gabapentin and Benign Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Use of gabapentinoid medications among US adults with cancer, 2005-2015.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Cancer Pain; Chronic Pain; Cross-Sectional S | 2020 |
Gabapentin for phantom limb pain after amputation in pediatric oncology: a systematic review protocol.
Topics: Amputation, Surgical; Analgesics; Child; Gabapentin; Humans; Neoplasms; Phantom Limb; Systematic Rev | 2021 |
Gabapentin enhances the antinociceptive effect of intrathecal morphine in refractory cancer pain patients.
Topics: Analgesics; Analgesics, Opioid; Cancer Pain; Drug Tolerance; Gabapentin; Humans; Morphine; Neoplasms | 2021 |
Gabapentin and Cancer Risk: Updated Findings from Kaiser Permanente Northern California.
Topics: Analgesics; California; Case-Control Studies; Cohort Studies; Databases, Factual; Female; Follow-Up | 2019 |
Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements?
Topics: Aged; Amines; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Chemotherapy, Adjuvant; C | 2015 |
Gabapentin in the treatment of hiccups in patients with advanced cancer: a 5-year experience.
Topics: Adult; Aged; Aged, 80 and over; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Dose- | 2010 |
New uses for older drugs: the tales of aspirin, thalidomide, and gabapentin.
Topics: Amines; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Aspirin; Cyclohexanecarboxylic Aci | 2010 |
[Pitfalls in the treatment of neuropathic pain in patients with cancer].
Topics: Aged; Amines; Amitriptyline; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Dr | 2011 |
Risk of cancer in patients exposed to gabapentin in two electronic medical record systems.
Topics: Aged; Aged, 80 and over; Amines; Anticonvulsants; California; Case-Control Studies; Cohort Studies; | 2012 |
The pattern of gabapentin use in a tertiary palliative care unit.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; G | 2003 |
[Gabapentin (Neurontin) and cancer pain: a pilot study].
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2004 |
Gabapentin in the treatment of severe sweating experienced by advanced cancer patients.
Topics: Adult; Aged; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Ami | 2006 |
Experience with gabapentin for neuropathic pain in adolescents: report of five cases.
Topics: Adolescent; Amines; Analgesics; Child; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminob | 2006 |
Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain.
Topics: Aged; Amines; Amitriptyline; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; | 2006 |
Survey of management of acquired nystagmus in the United Kingdom.
Topics: Amines; Baclofen; Cyclohexanecarboxylic Acids; Drug Utilization; Excitatory Amino Acid Antagonists; | 2007 |
Gabapentin for lancinating neuropathic pain.
Topics: Acetates; Acquired Immunodeficiency Syndrome; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabap | 1998 |
Gabapentin, an adjuvant treatment for neuropathic pain in a cancer hospital.
Topics: Acetates; Amines; Analgesics; Cancer Care Facilities; Cyclohexanecarboxylic Acids; Gabapentin; gamma | 2000 |
Differences in gabapentin efficacy for cancer pain more apparent than real?
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma | 2001 |
Gabapentin for opiod-related myoclonus in cancer patients.
Topics: Acetates; Amines; Analgesics, Opioid; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamm | 2001 |